Precision medicine is a patient-based “customized” medical model in which medical decisions and implementation are tailored to the individual characteristics of each patient, and disease diagnosis and treatment are based on the rational selection of the patient’s own genetic, molecular or cytological information. The tools used in precision medicine usually include molecular diagnostics, imaging, and corresponding software. The concept of precision medicine is an extension of “individualized medicine”, which is a more precise and individualized treatment based on biomolecules, and is tailored to the individual’s disease. The use of precision medicine in cancer patients has multiplied the survival time of many patients with advanced disease. The Precision Medicine Initiative is a new large-scale research and development program announced by Obama in his 2015 State of the Union address. The U.S. budget plans to allocate a total of$215 million to NIH, the U.S. Food and Drug Administration (FDA) and other agencies to fund scientific research, innovation and development in this area. in March 2015, China’s Ministry of Science and Technology held the first national expert meeting on precision medicine strategy, launched within this year and next, precision medicine program, finalized to invest RMB 60 billion by 2030 to carry out precision medicine research In March 2015, the Ministry of Science and Technology held the first national expert meeting on precision medicine strategy. Under the guidance of the concept of precision medicine, the Department of Neurosurgery of the First Affiliated Hospital of Soochow University is the first in China to carry out precision treatment of glioma based on. Precision resection of glioma is performed by 3D multimodal fusion technology combined with neuronavigation. Preoperatively, based on multiple imaging data from MRI CT, PET, combined with functional imaging DTI, Bold, the tumor and the nerve fibers that need to be protected are outlined, and intraoperative navigation combined with fluorescence microscopy is used to remove as much of the tumor as possible while achieving maximum functional protection. In the postoperative period, standard combined radiotherapy with temozolomide was used. After obtaining the specimen, we collaborated with Suzhou First Genetics to analyze all aspects of the genetic information of the tumor. This company was founded in June 2015 in Suzhou Nano Bio Park by two Chinese American scientists with high attainment in the field of gene sequencing and analysis. Through deep sequencing of the whole genome and high-throughput data calculation, each patient’s different mutated tumor driver gene is discovered, and the gene is queried for the availability of targeted drugs for that gene at home and abroad to carry out precision treatment. Mr. Wang is a patient in Changshu, aged only 35, who is the pillar of his family. At the beginning of this year, glioblastoma, the most malignant type of brain cancer, was discovered. After surgery, the resection was very thorough and the postoperative review was satisfactory. However, the pathology suggested that the value-added was very active. Despite six courses of radiotherapy, the tumor recurred and the speech started to be unpleasant. After Dr. Huang Yulun, the associate chief physician, performed genetic testing and state-of-the-art molecular imaging on him. His cancer driver gene, EGFR, was found and the molecular imaging confirmed the judgment of First Genetics’ analysis. Targeted drugs for this gene were tried with the consent of his family. Miraculously, the patient’s speech started to improve significantly after 4 days. Three weeks after taking the drug, the tumor shrank further on MRI and was cavernous and liquefied. The patient is currently under follow-up.